JP2018520092A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018520092A5 JP2018520092A5 JP2017557327A JP2017557327A JP2018520092A5 JP 2018520092 A5 JP2018520092 A5 JP 2018520092A5 JP 2017557327 A JP2017557327 A JP 2017557327A JP 2017557327 A JP2017557327 A JP 2017557327A JP 2018520092 A5 JP2018520092 A5 JP 2018520092A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- activatable antibody
- itga3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562156839P | 2015-05-04 | 2015-05-04 | |
| US62/156,839 | 2015-05-04 | ||
| US201562258870P | 2015-11-23 | 2015-11-23 | |
| US62/258,870 | 2015-11-23 | ||
| PCT/US2016/030864 WO2016179335A1 (en) | 2015-05-04 | 2016-05-04 | Anti-itga3 antibodies, activatable anti-itga3 antibodies, and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018520092A JP2018520092A (ja) | 2018-07-26 |
| JP2018520092A5 true JP2018520092A5 (https=) | 2019-06-20 |
Family
ID=57218629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017557327A Pending JP2018520092A (ja) | 2015-05-04 | 2016-05-04 | 抗ＩＴＧａ３抗体、活性化可能抗ＩＴＧａ３抗体、およびその使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10233244B2 (https=) |
| EP (1) | EP3292151A1 (https=) |
| JP (1) | JP2018520092A (https=) |
| CN (1) | CN107922490A (https=) |
| AU (1) | AU2016258988A1 (https=) |
| BR (1) | BR112017023868A2 (https=) |
| CA (1) | CA2984892A1 (https=) |
| HK (1) | HK1250037A1 (https=) |
| WO (1) | WO2016179335A1 (https=) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2892924B1 (en) * | 2012-06-14 | 2020-11-25 | Therapix Biosciences Ltd. | Humanized antibodies to cluster of differentiation 3 (cd3) |
| CN105722859B (zh) * | 2013-07-25 | 2021-05-07 | 西托姆克斯治疗公司 | 多特异性抗体、多特异性可活化抗体及其使用方法 |
| CA2925106C (en) | 2013-09-25 | 2023-11-14 | Cytomx Therapeutics, Inc. | Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof |
| IL270562B (en) * | 2014-01-31 | 2022-08-01 | Cytomx Therapeutics Inc | Polypeptide substrates that activate matriptase and u-plasminogen and other cleavable groups, preparations containing them and their uses |
| MA41374A (fr) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| CA2984892A1 (en) * | 2015-05-04 | 2016-11-10 | Cytomx Therapeutics, Inc. | Anti-itga3 antibodies, activatable anti-itga3 antibodies, and methods of use thereof |
| KR102726248B1 (ko) | 2016-07-07 | 2024-11-05 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
| WO2018097308A1 (ja) | 2016-11-28 | 2018-05-31 | 中外製薬株式会社 | リガンド結合活性が調整可能なリガンド結合分子 |
| TWI797097B (zh) | 2016-11-28 | 2023-04-01 | 日商中外製藥股份有限公司 | 包含抗原結合域與運送部分的多胜肽 |
| EA201991353A1 (ru) | 2016-12-09 | 2019-11-29 | Двухвалентные антитела, маскированные спирализованными спиралями | |
| CN111278461A (zh) | 2017-08-16 | 2020-06-12 | 百时美施贵宝公司 | 可前药化抗体、其前药以及使用和制备方法 |
| CN111511762B (zh) | 2017-08-21 | 2025-05-06 | 天演药业公司 | 抗cd137分子及其用途 |
| CN111630062A (zh) | 2017-11-28 | 2020-09-04 | 中外制药株式会社 | 具有可调节的配体结合活性的配体结合分子 |
| CN111836828B (zh) | 2017-11-28 | 2024-12-20 | 中外制药株式会社 | 包括抗原结合结构域和运送部分的多肽 |
| KR20200091901A (ko) * | 2017-12-01 | 2020-07-31 | 시애틀 지네틱스, 인크. | 암을 치료하기 위한 cd47 항체 및 이의 용도 |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| JP2021518603A (ja) | 2018-03-20 | 2021-08-02 | シートムエックス セラピューティクス，インコーポレイテッド | 哺乳動物対象における活性化可能抗体種の定量薬理学モデリングのためのシステムおよび方法 |
| AU2019271148B9 (en) | 2018-05-14 | 2025-05-29 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
| CA3100005A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| WO2019230868A1 (ja) | 2018-05-30 | 2019-12-05 | 中外製薬株式会社 | 単ドメイン抗体含有リガンド結合分子 |
| WO2019234694A2 (en) * | 2018-06-07 | 2019-12-12 | Magenta Therapeutics, Inc. | Therapeutic methods using antibody drug conjugates (adcs) |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| MY205459A (en) | 2018-12-06 | 2024-10-22 | Cytomx Therapeutics Inc | Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof |
| AU2020241686A1 (en) | 2019-03-15 | 2021-11-04 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
| KR20220023988A (ko) | 2019-05-14 | 2022-03-03 | 웨어울프 세라퓨틱스, 인크. | 분리 모이어티 및 이의 사용 방법 |
| JPWO2020246563A1 (https=) | 2019-06-05 | 2020-12-10 | ||
| US20220251206A1 (en) | 2019-06-11 | 2022-08-11 | Bristol-Myers Squibb Company | Anti-ctla4 antibody prodruggable (probody) at a cdr position |
| BR112022009110A2 (pt) | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
| BR112022019841A2 (pt) | 2020-04-09 | 2022-12-06 | Cytomx Therapeutics Inc | Composições contendo anticorpos ativáveis |
| AU2022367525A1 (en) | 2021-10-15 | 2024-05-02 | Amgen Inc. | Activatable polypeptide complex |
| WO2023183888A1 (en) | 2022-03-23 | 2023-09-28 | Cytomx Therapeutics, Inc. | Activatable antigen-binding protein constructs and uses of the same |
| US20250333487A1 (en) | 2022-03-25 | 2025-10-30 | Cytomx Therapeutics, Inc. | Activatable dual-anchored masked molecules and methods of use thereof |
| WO2023192973A1 (en) | 2022-04-01 | 2023-10-05 | Cytomx Therapeutics, Inc. | Activatable multispecific molecules and methods of use thereof |
| JP2025511187A (ja) | 2022-04-01 | 2025-04-15 | サイトムエックス セラピューティクス，インク． | Ｃｄ３結合タンパク質及びその使用方法 |
| US20260042849A1 (en) | 2022-08-01 | 2026-02-12 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
| AR130079A1 (es) | 2022-08-01 | 2024-10-30 | Cytomx Therapeutics Inc | Restos escindibles por proteasas, y métodos de uso de los mismos |
| TW202424183A (zh) | 2022-08-01 | 2024-06-16 | 美商Ｃｙｔｏｍｘ生物製藥公司 | 蛋白酶可切割受質及其使用方法 |
| JP2025525868A (ja) | 2022-08-01 | 2025-08-07 | サイトムエックス セラピューティクス，インク． | プロテアーゼ切断性部分及びその使用方法 |
| JP2025525879A (ja) | 2022-08-01 | 2025-08-07 | サイトムエックス セラピューティクス，インク． | プロテアーゼ切断性基質及びその使用方法 |
| EP4695281A1 (en) | 2023-04-12 | 2026-02-18 | CytomX Therapeutics, Inc. | Masking polypeptides, activatable cytokine constructs, and related compositions and methods |
| WO2024216146A1 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Masking polypeptides, activatable cytokine constructs, and related compositions and methods |
| WO2024216170A2 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| KR102574148B1 (ko) * | 2023-04-28 | 2023-09-05 | 주식회사 니오바이오파마슈티컬스 | 인테그린 표적 항체 및 이의 용도 |
| WO2025240659A2 (en) | 2024-05-14 | 2025-11-20 | Cytomx Therapeutics, Inc. | Activatable constructs, compositions and methods |
| WO2026020161A1 (en) | 2024-07-19 | 2026-01-22 | Cytomx Therapeutics, Inc. | Activatable il-12 constructs and related compositions and methods |
| WO2026024841A1 (en) | 2024-07-24 | 2026-01-29 | Astellas Us Llc | Bispecific antibodies that bind cd3 and muc1 and methods of use thereof |
| WO2026035650A2 (en) | 2024-08-05 | 2026-02-12 | Cytomx Therapeutics, Inc. | Cleavable polypeptides and methods of use thereof |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4643971A (en) | 1983-03-11 | 1987-02-17 | Sloan-Kettering Institute | Monoclonal antibodies to human bladder and ureter cancers and method |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4886745A (en) * | 1984-03-30 | 1989-12-12 | Syntex Inc. | Monoclonal antibody specific for human basal cell surface antigen |
| US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| DE3788058T2 (de) | 1986-08-28 | 1994-04-21 | Teijin Ltd | Zelltoxischer antikörperkomplex und verfahren zu seiner herstellung. |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| MD1367C2 (ro) | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| WO1998009651A1 (en) | 1996-09-03 | 1998-03-12 | Chugai Seiyaku Kabushiki Kaisha | ANTI-INTEGRIN α3 ANTIBODY COMPLEXES |
| WO2001091798A2 (en) | 2000-06-01 | 2001-12-06 | Universite Catholique De Louvain | Tumor activated prodrug compounds |
| ATE513563T1 (de) | 2000-10-09 | 2011-07-15 | Isis Innovation | Therapeutische und toleranz-induzierende antikörper |
| US20040109855A1 (en) | 2002-07-23 | 2004-06-10 | Herman Waldmann | Therapeutic antibodies with reduced side effect |
| US8809504B2 (en) | 2002-09-03 | 2014-08-19 | Vit Lauermann | Inhibitor which is deactivatable by a reagent produced by a target cell |
| US7736647B2 (en) | 2005-06-15 | 2010-06-15 | Monoclonal Antibodies Therapeutics | Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells |
| EP2535346B1 (en) | 2005-08-31 | 2017-08-02 | The Regents of The University of California | Cellular libraries of peptide sequences (CLiPS) and methods of using the same |
| JP2009529522A (ja) | 2006-03-10 | 2009-08-20 | ディアト | 酵素で切断可能なリンカーを介して抗体に複合された抗癌剤 |
| EP2975057A1 (en) | 2006-07-10 | 2016-01-20 | Fujita Health University | Novel anti-cd73 antibody |
| CA2697032C (en) | 2007-08-22 | 2021-09-14 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
| US20100189651A1 (en) * | 2009-01-12 | 2010-07-29 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
| US9309325B2 (en) | 2009-05-07 | 2016-04-12 | The Regents Of The University Of California | Antibodies and methods of use thereof |
| WO2013155605A1 (en) * | 2012-04-19 | 2013-10-24 | Innovascreen Inc. | Method for predicting a pathophysiological condition in an animal |
| CN104540518A (zh) * | 2012-04-27 | 2015-04-22 | 西托姆克斯治疗公司 | 结合表皮生长因子受体的可活化的抗体其使用方法 |
| WO2013192546A1 (en) | 2012-06-22 | 2013-12-27 | Cytomx Therapeutics, Inc. | Activatable antibodies having non-binding steric moieties and mehtods of using the same |
| US9309510B2 (en) | 2012-08-10 | 2016-04-12 | Cytomx Therapeutics, Inc. | Protease-resistant systems for polypeptide display and methods of making and using thereof |
| CA2984892A1 (en) * | 2015-05-04 | 2016-11-10 | Cytomx Therapeutics, Inc. | Anti-itga3 antibodies, activatable anti-itga3 antibodies, and methods of use thereof |
-
2016
- 2016-05-04 CA CA2984892A patent/CA2984892A1/en not_active Abandoned
- 2016-05-04 US US15/146,868 patent/US10233244B2/en not_active Expired - Fee Related
- 2016-05-04 CN CN201680038949.8A patent/CN107922490A/zh active Pending
- 2016-05-04 BR BR112017023868A patent/BR112017023868A2/pt not_active Application Discontinuation
- 2016-05-04 JP JP2017557327A patent/JP2018520092A/ja active Pending
- 2016-05-04 EP EP16722507.7A patent/EP3292151A1/en not_active Withdrawn
- 2016-05-04 AU AU2016258988A patent/AU2016258988A1/en not_active Abandoned
- 2016-05-04 WO PCT/US2016/030864 patent/WO2016179335A1/en not_active Ceased
- 2016-05-04 HK HK18109422.9A patent/HK1250037A1/zh unknown
-
2019
- 2019-01-18 US US16/251,919 patent/US20190309072A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018520092A5 (https=) | ||
| JP2018520091A5 (https=) | ||
| JP2018520991A5 (https=) | ||
| Shim | Bispecific antibodies and antibody–drug conjugates for cancer therapy: technological considerations | |
| CN103517719B (zh) | 抗体-药物缀合物 | |
| HRP20200721T1 (hr) | Aktivirajuća anti-cd166 antitijela i postupci njihove uporabe | |
| TWI872065B (zh) | 雙互補位ＦＲ－α抗體及免疫結合物 | |
| CN112851808B (zh) | Igf-1r抗体及其作为定位载体用于治疗癌症的用途 | |
| TWI787796B (zh) | 抗ｃｄ７１抗體類、可活化之抗ｃｄ７１抗體類及使用彼等之方法 | |
| CN114650844A (zh) | 抗cd47抗体、可活化抗cd47抗体及其使用方法 | |
| RU2015101803A (ru) | Перекрестно реактивные антитела к jagged 1/k jagged 2, активируемые антитела к jagged и способы их применения | |
| TWI822740B (zh) | 抗her2雙互補位抗體-藥物結合物及使用方法 | |
| TW201709932A (zh) | Ｃｄ１２３抗體及其共軛物 | |
| RS63276B1 (sr) | Supstrati koji mogu da se seku matriksnom metaloproteazom i serin proteazom i postupci njihove upotrebe | |
| CN103533957A (zh) | 抗liv-1的人源化抗体及其在治疗癌症中的用途 | |
| CN113302207A (zh) | Cd38和icam1抗体及其用途 | |
| TWI845724B (zh) | 用於偶聯的多肽複合物及其應用 | |
| CN117946278A (zh) | 多特异性抗体及其制备和使用方法 | |
| IL305954A (en) | Nectin-4 protein antibody and extacan compounds | |
| TW202221034A (zh) | 抗ｃｄ２２８抗體和抗體－藥物共軛體 | |
| JPWO2020086665A5 (https=) | ||
| TW202506193A (zh) | Trop2結合劑及其結合物 | |
| WO2025252100A1 (zh) | 一种自带游离载荷回收单元的配体药物偶联物 | |
| HK40130188A (zh) | Cd38和icam1抗体及其用途 | |
| HK40041667A (en) | Anti-her2 biparatopic antibody-drug conjugates and methods of use |